Compare Illumina, Inc. (ILMN) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Micron Technology, Inc. — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 29.3× Illumina, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Micron Technology, Inc. for 48 Days on average.
| ILMN | MU | |
|---|---|---|
Market Cap | $39.95B | $1.17T |
Volume | 3,169,503 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $293.69 | $1.21K |
52-Week Low | $91.00 | $181.60 |
Typical Hold Time | 83 Days | 48 Days |
Enterprise Value | $41.31B | $1.13T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Micron Technology (MU) trades at $1,035.84, down 4.79% today, but maintains strong bullish momentum with 500% gains over the past year. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $33.42 versus $31.77, and maintains impressive profitability with 63.8% net income margin. Technical indicators remain bullish overall despite recent pullback, with support at $1,020 and resistance at $1,064. The company's strategic customer agreements covering 35% of revenue through 2030 provide visibility into future growth.
Micron presents compelling investment potential driven by AI memory demand surge and strong financial performance, though risks include cyclical industry exposure and potential growth deceleration. Analyst consensus remains strongly bullish with 82.9% buy ratings and $1,590 price target, representing 53% upside. The stock's valuation at 13.94 P/E appears reasonable given projected revenue growth to $133.2B in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
